{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:18:24Z","timestamp":1778786304653,"version":"3.51.4"},"reference-count":39,"publisher":"Portland Press Ltd.","issue":"8","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The clinical data of safety and efficacy of a combined treatment with dimercaptosuccinic acid (DMSA) and Zinc with 2 years\u2019 follow-up in 60 neurological Wilson\u2019s disease (WD) patients was retrospectively analyzed. All the patients included in the present study were newly diagnosed and initialized with D-penicillamine (DPA) treatment but were found to have either neurological deterioration or allergy, and their treatment was switched to a combined treatment of DMSA and Zinc. Fifty-one patients (85%) had the neurological symptoms improved 1 and 2 years after treatment, 7 (11.67%) experienced a stable neurological condition, and 2 (3.33%) suffered deterioration of neurological symptoms. No early neurological deterioration was observed in all patients. Twenty-five percent patients experienced mild adverse reactions which did not require a discontinuation of the DMSA and Zinc treatment. Our study confirmed the safety and efficacy of the combined DMSA and Zinc therapy as an initial and probably long-term treatment in neurological WD patients.<\/jats:p>","DOI":"10.1042\/bsr20200654","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:40:38Z","timestamp":1592394038000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combined dimercaptosuccinic acid and zinc treatment in neurological Wilson\u2019s disease patients with penicillamine-induced allergy or early neurological deterioration"],"prefix":"10.1042","volume":"40","author":[{"given":"Xiao-Qun","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9454-9699","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"2021111620175366200_B1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/hepr.12301","article-title":"Pathogenesis and management of Wilson disease","volume":"44","author":"Harada","year":"2014","journal-title":"Hepatol. Res."},{"key":"2021111620175366200_B2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40846-015-0087-7","article-title":"Combination therapy using chelating agent and zinc for Wilson\u2019s disease","volume":"35","author":"Chen","year":"2015","journal-title":"J. Med. Biol. Eng."},{"key":"2021111620175366200_B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neuro.2015.05.004","article-title":"MRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamine","volume":"49","author":"Ranjan","year":"2015","journal-title":"Neurotoxicology"},{"key":"2021111620175366200_B4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000355276","article-title":"Worsening of Wilson disease following penicillamine therapy","volume":"71","author":"Kalita","year":"2014","journal-title":"Eur. Neurol."},{"key":"2021111620175366200_B5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2796.1991.tb00395.x","article-title":"Zinc sulphate therapy for Wilson\u2019s disease after acute deterioration during treatment with low-dose D-penicillamine","volume":"229","author":"Veen","year":"1991","journal-title":"J. Intern. Med."},{"key":"2021111620175366200_B6","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3225030951","article-title":"Penicillamine-associated cutis laxa and milia en plaque - case report and review of cutaneous changes associated with penicillamine","volume":"22","author":"Vajdi","year":"2016","journal-title":"Dermatol. Online J."},{"key":"2021111620175366200_B7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/bjd.13153","article-title":"Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by D-penicillamine in Wilson disease","volume":"171","author":"Ingen-Housz-Oro","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"2021111620175366200_B8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40257-013-0022-z","article-title":"Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects","volume":"14","author":"Ishak","year":"2013","journal-title":"Am. J. Clin. Dermatol."},{"key":"2021111620175366200_B9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2174\/1570159X14666151130222427","article-title":"Current drug managements of Wilson\u2019s disease: from west to east","volume":"14","author":"Li","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"2021111620175366200_B10","first-page":"497","article-title":"Experimental studies on the treatment of mercurial poisoning with alpha,alpha 1-dimercaptosuccinic acid","volume":"129","author":"Froitzheim","year":"1954","journal-title":"Dermatol. Wochenschr."},{"key":"2021111620175366200_B11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jtemb.2014.04.010","article-title":"Chelation therapy in intoxications with mercury, lead and copper","volume":"31","author":"Cao","year":"2015","journal-title":"J. Trace Elem. Med. Biol."},{"key":"2021111620175366200_B12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/15563650903174828","article-title":"Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning","volume":"47","author":"Bradberry","year":"2009","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"2021111620175366200_B13","first-page":"134","article-title":"Clinical analysis of 418 patients with Wilson\u2019s disease in traditional Chinese medicine and Western medicine therapy","volume":"10","author":"Yang","year":"1990","journal-title":"Zhong Xi Yi Jie He Za Zhi"},{"key":"2021111620175366200_B14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11655-012-1089-8","article-title":"Wilson\u2019s disease: update on integrated Chinese and Western medicine","volume":"19","author":"Li","year":"2013","journal-title":"Chinese J. Integr. Med."},{"key":"2021111620175366200_B15","first-page":"694","article-title":"Clinical curative effects of dimercaptosuccinic acid on hepatolenticular degeneration and the impact of DMSA on biliary trace elements","volume":"110","author":"Ren","year":"1997","journal-title":"Chin. Med. J. (Engl.)"},{"key":"2021111620175366200_B16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3748\/wjg.v4.i6.530","article-title":"Comparison of long lasting therapeutic effects between succimer and penicillamine on hepatolenticular degeneration","volume":"4","author":"Ren","year":"1998","journal-title":"World J. Gastroenterol."},{"key":"2021111620175366200_B17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11894-001-0041-4","article-title":"Treatment of Wilson\u2019s disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?","volume":"3","author":"Schilsky","year":"2001","journal-title":"Curr. Gastroenterol. Rep."},{"key":"2021111620175366200_B18","doi-asserted-by":"publisher","first-page":"1189.e1181","DOI":"10.1053\/j.gastro.2010.12.034","article-title":"Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease","volume":"140","author":"Weiss","year":"2011","journal-title":"Gastroenterology"},{"key":"2021111620175366200_B19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1756285616641598","article-title":"Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson\u2019s disease with D-penicillamine treatment failure","volume":"9","author":"Chen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"2021111620175366200_B20","doi-asserted-by":"publisher","first-page":"e0124569","DOI":"10.1371\/journal.pone.0124569","article-title":"Successful splenectomy for hypersplenism in Wilson\u2019s disease: a single center experience from China","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"},{"key":"2021111620175366200_B21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1055\/s-0031-1286056","article-title":"Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment","volume":"31","author":"Rosencrantz","year":"2011","journal-title":"Semin. Liver Dis."},{"key":"2021111620175366200_B22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2036.2003.01813.x","article-title":"Review article: diagnosis and current therapy of Wilson\u2019s disease","volume":"19","author":"Ferenci","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2021111620175366200_B23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1034\/j.1600-0676.2003.00824.x","article-title":"Diagnosis and phenotypic classification of Wilson disease","volume":"23","author":"Ferenci","year":"2003","journal-title":"Liver Int."},{"key":"2021111620175366200_B24","first-page":"S90","article-title":"Diagnosis of Wilson\u2019s disease - a 20 year audit","volume":"48","author":"Rathnayake","year":"2016","journal-title":"Pathology"},{"key":"2021111620175366200_B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2011.08.028","article-title":"Gender differences in Wilson\u2019s disease","volume":"312","author":"Litwin","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"2021111620175366200_B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11011-013-9378-2","article-title":"The effect of gender on brain MRI pathology in Wilson\u2019s disease","volume":"28","author":"Litwin","year":"2013","journal-title":"Metab. Brain Dis."},{"key":"2021111620175366200_B27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/B978-0-12-410502-7.00014-4","article-title":"Update on Wilson disease","volume":"110","author":"Aggarwal","year":"2013","journal-title":"Int. Rev. Neurobiol."},{"key":"2021111620175366200_B28","first-page":"197","article-title":"Chelation treatment of neurological Wilson\u2019s disease","volume":"86","author":"Walshe","year":"1993","journal-title":"QJM"},{"key":"2021111620175366200_B29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1478-3231.2010.02354.x","article-title":"Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation","volume":"31","author":"Bruha","year":"2011","journal-title":"Liver Int."},{"key":"2021111620175366200_B30","first-page":"743","article-title":"Neurological Wilson disease in children: a three years experience from Multan","volume":"61","author":"Noureen","year":"2011","journal-title":"JPMA"},{"key":"2021111620175366200_B31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jns.2015.06.010","article-title":"Early neurological worsening in patients with Wilson\u2019s disease","volume":"355","author":"Litwin","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"2021111620175366200_B32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/B978-0-444-52014-2.00049-5","article-title":"Wilson\u2019s disease","volume":"100","author":"Pfeiffer","year":"2011","journal-title":"Handb. Clin. Neurol."},{"key":"2021111620175366200_B33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/qjmed\/hcp114","article-title":"Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning","volume":"102","author":"Bradberry","year":"2009","journal-title":"QJM"},{"key":"2021111620175366200_B34","first-page":"683","article-title":"Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water","volume":"36","author":"Guha Mazumder","year":"1998","journal-title":"J. Toxicol."},{"key":"2021111620175366200_B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/07853899708998747","article-title":"The effect of 2,3 dimercaptosuccinic acid in the treatment of lead poisoning in adults","volume":"29","author":"Lifshitz","year":"1997","journal-title":"Ann. Med."},{"key":"2021111620175366200_B36","doi-asserted-by":"crossref","first-page":"e1001739","DOI":"10.1371\/journal.pmed.1001739","article-title":"Description of 3,180 courses of chelation with dimercaptosuccinic acid in children &lt;\/= 5 y with severe lead poisoning in Zamfara, Northern Nigeria: a retrospective analysis of programme data","volume":"11","author":"Thurtle","year":"2014","journal-title":"PLoS Med."},{"key":"2021111620175366200_B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1067\/mlc.2001.113037","article-title":"Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years","volume":"137","author":"Brewer","year":"2001","journal-title":"J. Lab. Clin. Med."},{"key":"2021111620175366200_B38","first-page":"849","article-title":"Treatment of Wilson\u2019s disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis","volume":"123","author":"Brewer","year":"1994","journal-title":"J. Lab. Clin. Med."},{"key":"2021111620175366200_B39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MPG.0b013e31821d5abe","article-title":"Zinc monotherapy from time of diagnosis for young pediatric patients with presymptomatic Wilson disease","volume":"53","author":"Mizuochi","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20200654\/891053\/bsr-2020-0654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20200654\/891053\/bsr-2020-0654.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T01:02:52Z","timestamp":1667005372000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/8\/BSR20200654\/225324\/Combined-dimercaptosuccinic-acid-and-zinc"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20200654","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,8]]},"article-number":"BSR20200654"}}